Publications
-
Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review.
Hoffman DA,
Debattista C, Valuck RJ, Iosifescu DV.
Neuropsychiatr Dis Treat.
2012:
8
277-84
-
The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.
DeBattista C,
Kinrys G, Hoffman D, Goldstein C, Zajecka J, Kocsis J, Teicher M, Potkin S, Preda A, Multani G, Brandt L, Schiller M, Iosifescu D, Fava M.
J Psychiatr Res.
2011;
45
(1):
64-75
-
Response to Dr. Tsai's letter to the Editor - The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.
Debattista C,
Hoffman DA.
J Psychiatr Res.
2010
-
Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.
DeBattista C,
DeBattista K.
Curr Drug Saf.
2010;
5
(3):
263-6
-
A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.
Blasey CM,
Debattista C, Roe R, Block T, Belanoff JK.
Contemp Clin Trials.
2009;
30
(4):
284-8
-
Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function.
Gomez RG,
Posener JA, Keller J, DeBattista C, Solvason B, Schatzberg AF.
Psychoneuroendocrinology.
2009;
34
(7):
1012-8
-
Utility of atypical antipsychotics in the treatment of resistant unipolar depression.
DeBattista C,
Hawkins J.
CNS Drugs.
2009;
23
(5):
369-77
-
Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial.
Nurnberg HG,
Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S.
JAMA.
2008;
300
(4):
395-404
-
Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness.
Fava M,
Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ.
Ann Clin Psychiatry.
2007 Jul-Sep;
19
(3):
153-9
-
Depression and smoking cessation: does the evidence support psychiatric practice?
Lembke A,
Johnson K, DeBattista C.
Neuropsychiatr Dis Treat.
2007;
3
(4):
487-93
-
Augmentation and combination strategies for depression.
DeBattista C,
J Psychopharmacol.
2006;
20
(3 Suppl):
11-8
-
Detecting psychotic major depression using psychiatric rating scales.
Keller J,
Gomez RG, Kenna HA, Poesner J, DeBattista C, Flores B, Schatzberg AF.
J Psychiatr Res.
2006;
40
(1):
22-9
-
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
DeBattista C,
Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G.
Biol Psychiatry.
2006;
60
(12):
1343-9
-
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
Thase ME,
Fava M, DeBattista C, Arora S, Hughes RJ.
CNS Spectr.
2006;
11
(2):
93-102
-
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe KL,
Block T, Debattista C, Blasey C, Belanoff JK.
Behav Brain Res.
2006;
171
(2):
225-9
-
The neuropsychological profile of psychotic major depression and its relation to cortisol.
Gomez RG,
Fleming SH, Keller J, Flores B, Kenna H, DeBattista C, Solvason B, Schatzberg AF.
Biol Psychiatry.
2006;
60
(5):
472-8
-
The use of mifepristone in the treatment of neuropsychiatric disorders.
DeBattista C,
Belanoff J.
Trends Endocrinol Metab.
2006;
17
(3):
117-21
-
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Fava M,
Thase ME, DeBattista C.
J Clin Psychiatry.
2005;
66
(1):
85-93
-
A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction.
DeBattista C,
Solvason B, Poirier J, Kendrick E, Loraas E.
J Clin Psychiatry.
2005;
66
(7):
844-8
-
C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
DeBattista C,
Belanoff J.
Curr Alzheimer Res.
2005;
2
(2):
125-9
-
Executive dysfunction in major depressive disorder.
DeBattista C,
Expert Rev Neurother.
2005;
5
(1):
79-83
-
The efficacy of divalproex sodium in the treatment of agitation associated with major depression.
Debattista C,
Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF.
J Clin Psychopharmacol.
2005;
25
(5):
476-9
-
Update on augmentation of antidepressant response in resistant depression.
DeBattista C,
Lembke A.
Curr Psychiatry Rep.
2005;
7
(6):
435-40
-
A prospective trial of modafinil as an adjunctive treatment of major depression.
DeBattista C,
Lembke A, Solvason HB, Ghebremichael R, Poirier J.
J Clin Psychopharmacol.
2004;
24
(1):
87-90
-
HPA axis activation in major depression and response to fluoxetine: a pilot study.
Young EA,
Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, Zubieta JK.
Psychoneuroendocrinology.
2004;
29
(9):
1198-204
-
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.
DeBattista C,
Solvason HB, Poirier J, Kendrick E, Schatzberg AF.
J Clin Psychopharmacol.
2003;
23
(1):
27-30
-
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
DeBattista C,
Doghramji K, Menza MA, Rosenthal MH, Fieve RR.
J Clin Psychiatry.
2003;
64
(9):
1057-64
-
Fetal heart rate decelerations during ECT-induced seizures: is it important?
DeBattista C,
Cochran M, Barry JJ, Brock-Utne JG.
Acta Anaesthesiol Scand.
2003;
47
(1):
101-3
-
Safety of antidepressants in the elderly.
Sommer BR,
Fenn H, Pompei P, DeBattista C, Lembke A, Wang P, Flores B.
Expert Opin Drug Saf.
2003;
2
(4):
367-83
-
Seizure duration with remifentanil/methohexital vs. methohexital alone in middle-aged patients undergoing electroconvulsive therapy.
Smith DL,
Angst MS, Brock-Utne JG, DeBattista C.
Acta Anaesthesiol Scand.
2003;
47
(9):
1064-6
-
The timing of electroconvulsive therapy and bispectral index after anesthesia induction using different drugs does not affect seizure duration.
Lemmens HJ,
Levi DC, Debattista C, Brock-Utne JG.
J Clin Anesth.
2003;
15
(1):
29-32
-
Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.
Belanoff JK,
Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF.
J Mol Neurosci.
2002 Aug-Oct;
19
(1-2):
201-6
-
An open label trial of C-1073 (mifepristone) for psychotic major depression.
Belanoff JK,
Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF.
Biol Psychiatry.
2002;
52
(5):
386-92
-
Cortisol feedback during the HPA quiescent period in patients with major depression.
Posener JA,
DeBattista C, Williams GH, Schatzberg AF.
Am J Psychiatry.
2001;
158
(12):
2083-5
-
Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder?
DeBattista C,
Mueller K.
J ECT.
2001;
17
(2):
91-8
-
Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia.
Glick ID,
Suppes T, DeBattista C, Hu RJ, Marder S.
Ann Intern Med.
2001;
134
(1):
47-60
-
Sertraline versus imipramine to prevent relapse in chronic depression.
Koran LM,
Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB.
J Affect Disord.
2001;
65
(1):
27-36
-
24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression.
Posener JA,
DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF.
Arch Gen Psychiatry.
2000;
57
(8):
755-60
-
Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study.
DeBattista C,
Posener JA, Kalehzan BM, Schatzberg AF.
Am J Psychiatry.
2000;
157
(8):
1334-7
-
Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness.
Schatzberg AF,
Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK.
Am J Psychiatry.
2000;
157
(7):
1095-100
-
Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.
DeBattista C,
Solvason HB, Breen JA, Schatzberg AF.
J Clin Psychopharmacol.
2000;
20
(2):
274-5
-
Negative-pressure pulmonary edema: a potential hazard in patients undergoing ECT.
Cochran M,
DeBattista C, Schmiesing C, Brock-Utne JG.
J ECT.
1999;
15
(2):
168-70
-
Phenomenology and treatment of agitation.
Schatzberg AF,
DeBattista C.
J Clin Psychiatry.
1999:
60 Suppl 15
17-20
-
The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.
Crismon ML,
Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME.
J Clin Psychiatry.
1999;
60
(3):
142-56
-
Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP).
Trivedi MH,
DeBattista C, Fawcett J, Nelson C, Osser DN, Stein D, Jobson K.
Psychopharmacol Bull.
1998;
34
(3):
355-9
-
ECT in dissociative identity disorder and comorbid depression.
DeBattista C,
Solvason HB, Spiegel D.
J ECT.
1998;
14
(4):
275-9
-
Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs.
DeBattista C,
Sofuoglu M, Schatzberg AF.
Biol Psychiatry.
1998;
44
(5):
341-7
-
Treatment of psychotic depression.
Debattista C,
Solvason HB, Belanoff J, Schatzberg AF.
Am J Psychiatry.
1997;
154
(11):
1625-6
-
Development of obsessive symptoms during nefazodone treatment.
Sofuoglu M,
Debattista C.
Am J Psychiatry.
1996;
153
(4):
577-8
-
Physical symptoms associated with paroxetine withdrawal.
Debattista C,
Schatzberg AF.
Am J Psychiatry.
1995;
152
(8):
1235-4
-
Sumatriptan prophylaxis for postelectroconvulsive therapy headaches.
DeBattista C,
Mueller K.
Headache.
1995;
35
(8):
502-3
Help